<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-77579</identifier>
<setSpec>0214-3429</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Anidulafungin</dc:title>
<dc:description xml:lang="en">Anidulafungin is a new echinocandin antifungal agentrecently approved in Spain by the Spanish Drug Agency.As other echinocandins, it inhibits a selective target, 1,3-&amp;#946;-D-glucan synthesis, a major structural component ofthe fungal cell wall which is not present in mammaliancells, this avoiding toxicity problems. It has fungicidalactivity against many Candida spp., including fluconazole-resistant, and fungistatic activity against otheryeast and moulds such as Aspergillus spp. Clinical trialshave shown non-inferiority of anidulafungin to fluconazolefor invasive, including candidemia, and non-invasiveCandida infections. It is well-tolerated, and no drug-relatedserious adverse events have been reported. Anidulafungin,which has a very long half life, is slowly degradedby human peptidases and proteases and has alow drug&#150;drug interaction profile based on its lack ofinteraction with the cytochrome P450 system. Thus, dosingadjustments of anidulafungin based on age, gender,body weight, disease status, concomitant therapy or renalor hepatic insufficiency is not necessary. As it doesnot interact with amphotericin B and voriconazole,cyclosporine, tacrolimus and other drugs, it can be usedin combination with other antifungal agents and co-administeredwith immunosuppressant drugs.It is generally well-tolerated in clinical trials. Itsmost frequent adverse events are nausea, vomiting, moderate diarrhea, transient elevation of hepatic enzymesand headache. Some of the patients have mild, passingreactions such as facial blushing, nausia and dyspnia relatedwith rapid intravenous perfusion.Its antifungal activity, clinical efficacy, safety profile,and pharmacokinetic characteristics make it a suitablealternative antifungal compound for therapy of mucosalcandidiasis, candidemia and invasive candidiasis, aboveall in patients with some degree of renal and hepatic insufficiency (AU)</dc:description>
<dc:creator>Gobernado, M</dc:creator>
<dc:creator>Cantón, E</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La anidulafungina es una nueva equinocandina de aprobaciónreciente por la Agencia Española del Medicamento.Como otras equinocandinas, inhibe de manera selectiva lasíntesis del 1,3-&amp;#946;-D-glucano, un importante componenteestructural de la pared de la célula fúngica que no está presenteen la de los mamíferos, lo que evita problemas de toxicidad.La actividad antifúngica frente a la mayoría deCandida spp. es fungicida, incluyendo las resistentes a fluconazol,y fungistática sobre Aspergillus spp. y otros hongosfilamentosos. Los ensayos clínicos han demostrado buenaeficacia en candidiasis orofaríngeas y esofagitis, así como encandidiasis invasoras, incluyendo candidemias, con eficaciaigual o superior al fluconazol. La anidulafungina es bien toleraday cuenta con mínimos efectos adversos. El fármaco,con una semivida muy larga, se degrada en el organismohumano lentamente por medio de peptidasas y proteasas ytiene un perfil bajo de interacciones medicamentosas al noser sustrato, inductor o interactuar con las isoenzimas delsistema citocromo P450. Por tanto, no es necesario su ajustede dosis en función de edad, sexo, peso corporal, estadode la enfermedad, terapia concomitante o insuficiencia renalo hepática. Al no interactuar con amfotericina B, voriconazol,ciclosporina, tacrolimus y otros fármacos, la anidulafunginapuede coadministrarse con otros agentes antifúngicos yfármacos inmunosupresores.La anidulafungina es generalmente bien tolerada en losensayos clínicos. Los efectos adversos más frecuentes sonnáuseas, vómitos, diarrea moderada, elevación transitoriade las enzimas hepáticas y cefalea (AU)</dc:description>
<dc:source>Rev Esp Quimioter;21(2): 99-114, jun. 2008. ilus, tab, graf</dc:source>
<dc:identifier>ibc-77579</dc:identifier>
<dc:title xml:lang="es">Anidulafungina</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d943^s22038</dc:subject>
<dc:subject>^d9373^s22011</dc:subject>
<dc:subject>^d9373^s22032</dc:subject>
<dc:subject>^d943^s22065</dc:subject>
<dc:subject>^d943^s22000</dc:subject>
<dc:subject>^d943^s28898</dc:subject>
<dc:subject>^d943^s22078</dc:subject>
<dc:subject>^d943^s22079</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d943^s22073</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d2208^s22052</dc:subject>
<dc:subject>^d2208^s22011</dc:subject>
<dc:subject>^d2208^s22021</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d2208^s29165</dc:subject>
<dc:subject>^d19059</dc:subject>
<dc:subject>^d9373^s22067</dc:subject>
<dc:type>article</dc:type>
<dc:date>200806</dc:date>
</metadata>
</record>
</ibecs-document>
